World-leading NAD specialists join NADMED to advance redox metabolite diagnostics

As interest in the clinical relevance of redox metabolism grows, the need for reliable measurement tools is becoming increasingly critical. NADMED’s Scientific Advisory Board brings together globally recognized experts to guide development of diagnostics to reveal metabolic dysfunction and support earlier, more precise insights into health and disease.   NADMED, a Finnish biotechnology company specializing in precision measurement of redox metabolites, has established a Scientific Advisory Board (SAB) composed of internationally recognized experts in metabolism, mitochondrial medicine, and clinical diagnostics. The board will guide the company’s research and development efforts as it advances precision diagnostics and therapies related to metabolism, mitochondrial function, chronic disease, and personalized medicine.   Founded in 2022 as a spinout from the University of Helsinki, NADMED has developed the first CE-marked diagnostic solutions that measure all four nicotinamide adenine dinucleotide (NAD) coenzymes directly from biological samples, including fresh blood. Mitochondrial dysfunction, altered NAD metabolism, and disrupted redox balance are increasingly linked to a wide range of conditions, from rare genetic disorders to neurological disease and chronic conditions, yet remain opaque with existing clinical tools.   The Scientific Advisory Board will support NADMED in addressing this gap by providing guidance on scientific strategy, research priorities, and potential clinical pathways.   The new Scientific Advisory Board is led by Professor Charles Brenner, a leading authority on NAD metabolism and Alfred E Mann Family Foundation Chair in Diabetes & Cancer Metabolism, Beckman Research Institute at City of Hope. Along with Professor Rita Horvath, Professor of Neurogenetics, Department of Clinical Neurosciences at the University of Cambridge, specializing in mitochondrial disease, and Dr Helen Messier, physician-scientist and Chief Medical Officer at Bioscope.ai, with expertise in precision medicine and clinical applications of metabolomics.   Professor Charles Brenner commented, “Measuring NAD and related metabolites in blood provides a long-missing connection between basic metabolism and human health. The ability to advance these kits into broad clinical use will open new avenues for understanding disease mechanisms and monitoring interventions.”   For clinicians treating complex neurological disorders, the ability to quantify metabolic stress in patients represents a shift in what can be assessed and monitored. Professor Rita Horvath added, “Mitochondrial dysfunction is central to many neurological conditions. With accessible and reproducible measurements of redox metabolites, we can begin to evaluate these processes directly in patients in ways that were not previously feasible.”   The SAB’s clinical perspective spans beyond rare and genetic disorders to emerging areas of preventive and precision health. Dr Helen Messier commented, “Precision health depends on biomarkers that can guide individualized care. Reliable measurement of NAD and redox metabolites could enhance how we detect early dysfunction, track interventions, and understand patient variability.”   The team at NADMED view the Scientific Advisory Board as an essential step in refining the scientific, clinical, and regulatory pathways for redox metabolite diagnostics.   Jari Närhi, CEO of NADMED, commented, “We are honored to work with these leaders in metabolism, neurology, and precision medicine. Their insights will help ensure that the science guiding our work is held to the highest standard, as we collaborate with researchers and clinicians to advance the measurement of redox biology in medicine.”   The global market for metabolomics and redox-metabolite diagnostics is projected to grow from around USD 4.3 billion in 2025 to USD 14.4 billion by 2034. By establishing a world-class Scientific Advisory Board, NADMED aims to help meet this growing global demand, supporting researchers, clinicians, and patients with robust, scalable NAD testing.